BIIB129, is a unique brain-penetrant covalent inhibitor of Bruton’s tyrosine kinase (BTK), with high kinome selectivity. It exhibits efficacy in targeting B-cell proliferation in the central nervous system (CNS), making it a promising immunomodulatory therapy for multiple sclerosis (MS).

CVN293 is a potent, selective, and brain permeable small-molecule inhibitor of potassium (K+) ion channel KCNK13 with an IC50s of 49 nM and 28 nM for hKCNK13 and mKCNK13, respectively. It also inhibits NOD-like receptor protein 3 (NLRP3) inflammasome-mediated IL-1ß production in LPS-stimulated primary neonatal murine microglia with an IC50 of 24 nM and has […]

CVN293 is a potent, selective, and brain permeable small-molecule inhibitor of potassium (K+) ion channel KCNK13 with an IC50s of 49 nM and 28 nM for hKCNK13 and mKCNK13, respectively. It also inhibits NOD-like receptor protein 3 (NLRP3) inflammasome-mediated IL-1ß production in LPS-stimulated primary neonatal murine microglia with an IC50 of 24 nM and has […]

BIIB129, is a unique brain-penetrant covalent inhibitor of Bruton’s tyrosine kinase (BTK), with high kinome selectivity. It exhibits efficacy in targeting B-cell proliferation in the central nervous system (CNS), making it a promising immunomodulatory therapy for multiple sclerosis (MS).

Oditrasertib (DNL-788, SAR 443820) is a first-in-class, selective, orally bioavailable, brain penetrant inhibitor of Receptor-interacting serine/threonine protein kinase 1 (RIPK1). It can be used in research of myotrophic lateral sclerosis and multiple sclerosis.

CVN293 is a potent, selective, and brain permeable small-molecule inhibitor of potassium (K+) ion channel KCNK13 with an IC50s of 49 nM and 28 nM for hKCNK13 and mKCNK13, respectively. It also inhibits NOD-like receptor protein 3 (NLRP3) inflammasome-mediated IL-1ß production in LPS-stimulated primary neonatal murine microglia with an IC50 of 24 nM and has […]

CVN293 is a potent, selective, and brain permeable small-molecule inhibitor of potassium (K+) ion channel KCNK13 with an IC50s of 49 nM and 28 nM for hKCNK13 and mKCNK13, respectively. It also inhibits NOD-like receptor protein 3 (NLRP3) inflammasome-mediated IL-1ß production in LPS-stimulated primary neonatal murine microglia with an IC50 of 24 nM and has […]

Oditrasertib (DNL-788, SAR 443820) is a first-in-class, selective, orally bioavailable, brain penetrant inhibitor of Receptor-interacting serine/threonine protein kinase 1 (RIPK1). It can be used in research of myotrophic lateral sclerosis and multiple sclerosis.

Oditrasertib (DNL-788, SAR 443820) is a first-in-class, selective, orally bioavailable, brain penetrant inhibitor of Receptor-interacting serine/threonine protein kinase 1 (RIPK1). It can be used in research of myotrophic lateral sclerosis and multiple sclerosis.

Oditrasertib (DNL-788, SAR 443820) is a first-in-class, selective, orally bioavailable, brain penetrant inhibitor of Receptor-interacting serine/threonine protein kinase 1 (RIPK1). It can be used in research of myotrophic lateral sclerosis and multiple sclerosis.